PTC Therapeutics, Inc. reported $1.01B of revenue over the trailing twelve months, −43% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $1.01B (to Q2 2026). Net income: −$38M, trailing twelve months to Q2 2026. Free cash flow: −$40M, trailing twelve months to Q2 2026. Operating margin: 4.0%, trailing twelve months to Q2 2026.

PTCTPTC Therapeutics, Inc.

Healthcare

$64.70+7.0% 1Y

$64.70

$57.8452 weeks$86.25

PTCT as reported

PTC Therapeutics, Inc. reported $1.01B of revenue over the trailing twelve months, −43% on the year before. 11 reported series are charted on this page, each one as filed.

$1.01B

Revenue, trailing twelve months · to Q2 2026 · −43% against the twelve months before

Net income: −$38M
Net income · −106% year on year · trailing twelve months to Q2 2026
Free cash flow: −$40M
Free cash flow · −106% year on year · trailing twelve months to Q2 2026
Operating margin: 4.0%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for PTCT, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$1.01B	−43%	Q2 2026
Net income	−$38M	−106%	Q2 2026
EPS	−$0.58	−108%	Q2 2026
Gross margin	96%	n/a	Q4 2019 · 26 quarters behind
Operating margin	4.0%	n/a	Q2 2026
Net margin	−13%	n/a	Q2 2026
ROE	−172%	n/a	Q2 2026
ROA	11%	n/a	Q2 2026
ROIC	−20%	n/a	Q2 2026
Free cash flow	−$40M	−106%	Q2 2026
P/E	7.95	n/a	Q4 2025

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.